Cyteir Therapeutics
Cambridge
About Cyteir Therapeutics
Cyteir is a clinical-stage oncology company that is focused on the discovery and development of next-generation synthetically lethal therapies to treat cancer. The company is using its expertise in DNA damage response biology to advance a pipeline of novel drug candidates that selectively target key cancer vulnerabilities. Cyteir’s wholly owned lead compound, CYT-0851, is a potent and selective, oral investigational drug that was designed to inhibit RAD51-mediated homologous recombination and the repair of double-strand DNA breaks.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $156.7M
- Funding stage: IPO
- Last round: Series C (Feb 2021)
- Ticker: nasdaq:CYT
- Website: cyteir.com
- Phone: 312-953-3651
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/cyteir-therapeutics-19262 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.